[
  {
  "id": "NCT05118789",
  "title": "A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors (ARROS-1)",
  "phase": "PHASE1, PHASE2",
  "description": "Phase 1/2, dose escalation and expansion study designed to evaluate the safety, tolerability, and antitumor activity of zidesamtinib (NVL-520) in patients with advanced ROS1-rearranged NSCLC and other solid tumors. Phase 1 determines the recommended Phase 2 dose (RP2D) and maximum tolerated dose (MTD). Phase 2 evaluates objective response rate (ORR) and other efficacy endpoints across multiple expansion cohorts.",
  "inclusion_criteria": [
    "Inclusion Criteria:",
    "",
    "* Age ≥18 years (Cohort 2e: Age ≥12 years).",
    "* Phase 1: Histologically or cytologically confirmed locally advanced or metastatic solid tumor with documented ROS1 rearrangement.",
    "* Phase 2 (Cohorts 2a–2d): Histologically or cytologically confirmed locally advanced or metastatic NSCLC with ROS1 rearrangement.",
    "* Phase 2 (Cohort 2e): Histologically or cytologically confirmed locally advanced or metastatic solid tumor other than NSCLC with ROS1 rearrangement.",
    "* Prior anticancer treatment allowed according to cohort definition (except Cohort 2a).",
    "* Phase 1: Evaluable disease per RECIST 1.1.",
    "* Phase 2: Measurable disease per RECIST 1.1.",
    "* Adequate baseline organ function and bone marrow reserve."
  ],
  "exclusion_criteria": [
    "Exclusion Criteria:",
    "",
    "* Presence of a known oncogenic driver alteration other than ROS1.",
    "* Known allergy or hypersensitivity to excipients of NVL-520.",
    "* Major surgery within 4 weeks prior to first dose of study drug.",
    "* Ongoing anticancer therapy.",
    "* Actively receiving systemic treatment or direct medical intervention in another therapeutic clinical study."
  ],
  "gender": "All",
  "min_age": "18 Years",
  "max_age": "Not specified",
  "status": "RECRUITING",
  "start_date": "2022",
  "completion_date": "Not specified",
  "sponsor": "Unknown",
  "last_updated": "Not specified"
  },
  {
    "id": "NCT05224141",
    "title": "A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination With Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination With Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer",
    "phase": "PHASE3",
    "description": "No description provided.",
    "inclusion_criteria": [
      "Inclusion Criteria:",
      "",
      "* Has histologically or cytologically confirmed diagnosis of ES-SCLC in need of first-line therapy",
      "* Has ES-SCLC defined as Stage IV (T any, N any, M1a/b/c) by the American Joint Committee on Cancer, Eighth Edition or T3-T4 due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan",
      "* Males agree to use contraception, refrain from donating sperm, and abstain from heterosexual intercourse",
      "* Females are not pregnant or breastfeeding, is not a woman of childbearing potential (WOCBP) or is a WOCBP who uses a highly effective contraceptive method, or is abstinent from heterosexual intercourse",
      "* Has measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1",
      "* Has a predicted life expectancy of \\>3 months",
      ""
    ],
    "exclusion_criteria": [
    
      "Exclusion Criteria:",
      "",
      "* Is considered a poor medical risk due to a serious, uncontrolled medical disorder or non-malignant systemic disease",
      "* Has received prior treatment for Small Cell Lung Cancer (SCLC)",
      "* Is expected to require any other form of antineoplastic therapy for SCLC while on study",
      "* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention",
      "* Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration",
      "* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication",
      "* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years",
      "* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis",
      "* Has a history of severe hypersensitivity reaction (≥Grade 3) to any study intervention and/or any of its excipients",
      "* Has an active autoimmune disease that has required systemic treatment in past 2 years",
      "* Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease",
      "* Has a known history of, or active, neurologic paraneoplastic syndrome",
      "* Has an active infection requiring systemic therapy",
      "* Has a known history of human immunodeficiency virus (HIV) infection",
      "* Has a known history of Hepatitis B or known active Hepatitis C virus infection",
      "* Has had an allogenic tissue/solid organ transplant",
      "* Has had major surgery within prior 3 weeks or has not recovered adequately from toxicity and/or complications from an intervention prior to receiving the first dose of study intervention",
      "* Has symptomatic ascites or pleural effusion"
    ],
    "gender": "All",
    "min_age": "18 Years",
    "max_age": "Not specified",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2022-03-24",
    "completion_date": "2027-06-07",
    "sponsor": "Unknown",
    "last_updated": "2025-02-03"
  },
  {
    "id": "NCT05261399",
    "title": "A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON).",
    "phase": "PHASE3",
    "description": "No description provided.",
    "inclusion_criteria": [
      "Inclusion Criteria:",
      "",
      "* Provision of signed and dated written ICF prior to any mandatory and non-mandatory study-specific procedures, sampling and analyses.",
      "* Participant must be ≥18 years (≥ 19 years of age in South Korea) at the time of signing the informed consent. All genders are permitted.",
      "* Histologically or cytologically confirmed locally advanced or metastatic NSCLC which is not amenable to curative therapy.",
      "* Must have at least one documented sensitising EGFR mutation: exon19 deletion, L858R mutation, and/or T790M.",
      "* Documented radiologic progression on first- or second-line treatment with osimertinib as the most recent anti-cancer therapy.",
      "* Mandatory provision of FFPE tumour tissue.",
      "* MET overexpression and/or amplification in tumour specimen collected following progression on prior osimertinib treatment.",
      "* Measurable disease as defined by RECIST 1.1.",
      "* Adequate haematological, liver, renal and cardiac functions, and coagulation parameters.",
      "* ECOG performance status of 0 or 1.",
      ""
    ],
    "exclusion_criteria": [
      "Exclusion Criteria:",
      "",
      "* Predominant squamous NSCLC, and small cell lung cancer.",
      "* Prior or current treatment with a third-generation EGFR-TKI other than Osimertinib.",
      "* Prior or current treatment with savolitinib or another MET inhibitors.",
      "* Spinal cord compression or brain metastases, unless asymptomatic and are stable.",
      "* History or active leptomeningeal carcinomatosis.",
      "* Unresolved toxicities from any prior therapy greater than CTCAE Grade 1 and prior platinum-therapy related Grade 2 neuropathies with the exception of alopecia and haemoglobin ≥ 9.0 g/dL.",
      "* Active/unstable cardiac diseases currently or within the last 6 months, clinically significant ECG abnormalities, and/or factors/medications that may affect QTc intervals.",
      "* History of liver cirrhosis of any origin and clinical stage; or history of other serious liver disease or chronic disease with relevant liver involvement.",
      "* Known serious active infection including, but not limited to, tuberculosis, or HIV, HBV or HCV or gastrointestinal disease.",
      "* Receipt of live attenuated vaccine (including against COVID-19) within 30 days prior to the first dose of study intervention.",
      "* Past medical history of ILD, drug-induced ILD, radiation pneumonitis, which required steroid treatment, or any evidence of clinically active ILD.",
      "* Participants currently receiving medications or herbal supplements known to be strong inducers of cytochrome P450 (CYP)3A4 or strong inhibitors of CYP1A2."
    ],
    "gender": "All",
    "min_age": "18 Years",
    "max_age": "130 Years",
    "status": "RECRUITING",
    "start_date": "2022-08-03",
    "completion_date": "2026-12-17",
    "sponsor": "Unknown",
    "last_updated": "2025-01-10"
  },
  {
    "id": "NCT05789082",
    "title": "A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation (Krascendo 170).",
    "phase": "PHASE Ib/II",
    "description": "The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of divarasib combined with other anti-cancer therapies in participants with previously untreated, advanced or metastatic non-small cell lung cancer (NSCLC).",
    "inclusion_criteria": [
      "Inclusion Criteria:",
      "",
      "* Confirmation of Biomarker eligibility",
      "* Pre-treatment tumor tissue along with an associated pathology report is required for all participants enrolled on study. Representative tumor specimens must be in formalin-fixed, paraffin embedded (FFPE) blocks (preferred) or 15 unstained, freshly cut, serial slides. Although 15 slides are required, if only 10 slides are available, the participant may be eligible for the study following consultation with the Sponsor.",
      "* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1",
      "* Histologically or cytologically documented locally advanced unresectable or metastatic NSCLC that is not eligible for curative surgery and/or definitive chemoradiotherapy",
      "* No prior systemic treatment for advanced unresectable or metastatic NSCLC",
      "* Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1",

      ""
    ],
    "exclusion_criteria": [
      "Exclusion Criteria:",
      "",
      "* Known concomitant second oncogenic driver with available targeted treatment",
      "* Squamous cell histology NSCLC", 
      "* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases",
      "* Prior treatment with a KRAS G12C inhibitor",
      "* Known hypersensitivity to any of the components of divarasib or pembrolizumab; or known hypersensitivity to pemetrexed, carboplatin, or cisplatin (Cohort B only)",
      "* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis, active tuberculosis, significant cardiovascular disease within 3 months prior to initiation of study treatment",
      "* History of malignancy other than NSCLC within 5 years prior to initiation of study treatment, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate more >90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal breast carcinoma in situ, or Stage I uterine cancer",
      "* Uncontrolled tumor related pain, pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures, uncontrolled or symptomatic hypercalcemia",
    ""
    ],
    "gender": "All",
    "min_age": "18 Years",
    "max_age": "130 Years",
    "status": "RECRUITING",
    "start_date": "2022-08-03",
    "completion_date": "2026-12-17",
    "sponsor": "Unknown",
    "last_updated": "2025-01-10"
  }
]